The Acro Merger: Growth Engine or Lender-Consent Test

Not a Ratio Test, a Consent Test

The main article already described 2026 as a year in which Israel Canada would be tested not only on execution but also on financing. This follow-up isolates only the financing side of the Acro merger. The question here is not whether the transaction looks strategically attractive on paper, but whether the lender layer will allow it to close without reopening the funding terms.

That matters because the transaction is much heavier than a standard merger headline suggests. Acro is supposed to merge into Israel Canada so that all of its assets and liabilities move into the company as they are, including its bond obligations. The consideration itself is structured as 40% cash and 60% shares, with a cash leg of roughly NIS 1.24 billion and 91,947,958 Israel Canada shares to be issued, equal to 21.23% of the company after issuance.

That already brings the core point into focus. This is not only a growth deal. It is also a financing-and-consent deal that has to survive a long interim period. Under the agreement, closing cannot happen before September 10, 2026, and the extension mechanism can push the outside date to the end of 2026 and in any case no later than February 28, 2027. So the real question is not only whether Israel Canada can afford Acro in theory, but whether it can carry the deal path cleanly until closing.

Acro Is Not Arriving Alone, It Is Arriving with Its Liabilities

This is the main difference between a superficial read and the right one. It is easy to focus only on the cash leg and assume the financing question is mainly whether Israel Canada can raise enough money to pay for the deal. The picture is broader: the company is expected to absorb Acro with all of its liabilities, including Acro's bond obligations, while Acro bondholders are expected to receive new Israel Canada bond series on the same terms.

In other words, the financing test here is not only a question of cash on hand or of a single raise. It is a test of absorbing liabilities, preserving lender confidence, and getting through a long interim period without an event that forces the financing framework to be reopened. That also explains why the closing conditions include approvals from Israel Canada's and Acro's financiers, not only shareholder and regulatory approvals.

The March 16, 2026 trustee notice also has to be read correctly. This was not a standard bondholder vote request. It opened a creditor objection channel. The trustee cited Section 319 of the Companies Law, under which a court may delay or block a merger if there is a reasonable concern that the surviving company will not be able to meet the obligations of the merged entity. So even though this is not a formal bondholder approval step, it is a clear sign that the merger has already moved from headline logic into creditor-risk management.

The Reported Covenants Still Have Room

This is the part that is easiest to miss. Someone reading only the debt table could think the deal is stuck because Israel Canada is already too close to breaching covenants. That is not the situation. On the contrary, the disclosed financial covenants against a local bank still show room: consolidated equity of NIS 2.689 billion against a NIS 1.2 billion minimum, a consolidated equity-to-assets ratio of 21% against a 17% floor, a solo equity-to-assets ratio of 62.4% against a 37.5% floor, and another consolidated ratio of 26.5% against a 22% floor.

That chart matters because it changes the diagnosis. This is not currently a ratio-breach distress case. It is a lender-control case. In the same covenant disclosure, the company lists a commitment not to execute a merger without the bank's prior written consent. It then adds that the Acro deal requires consent from financing parties, including the current financing party, in connection with Rosen and Tuchmair's holdings falling below 32% of the company's issued and paid-up share capital. As of the report date, that consent had not yet been obtained.

That distinction is critical. If the numerical covenants were already close to failure, the thesis would be that the company is approaching a balance-sheet wall. The numbers tell a different story. The reported ratio room still exists, yet the deal still needs discrete lender signatures because it creates an effective control-dilution event and because the merger itself requires approval. So the bottleneck is not a cracked accounting metric. It is the ability to close a financing-consent chain around a deal that dilutes control and pulls in additional liabilities.

There is another layer. The company itself says its credit agreements include cross-default language and technical, non-financial default triggers as well. It adds that it does not view an immediate-acceleration scenario as highly likely, but the fact that it stresses this point reinforces the right read: in the Acro merger, the key test is not whether the ratio table still looks fine, but whether the surrounding approval chain stays clean.

Recent Capital Raises Help, but They Do Not by Themselves Close a NIS 1.24 Billion Cash Leg

There is real financing activity around this story, but it has to be framed carefully. In January 2025 Israel Canada completed a private share placement of roughly NIS 125 million. In May 2025 it expanded Series H bonds by NIS 200 million par value, and in September 2025 it expanded the same series again by roughly NIS 147.2 million par value. After the balance-sheet date, on January 29, 2026, it also completed a private share placement to Harel for roughly NIS 180 million.

That chart does not prove that Israel Canada lacks the whole cash leg, and it also does not prove that those capital raises were earmarked for the Acro transaction. In fact, the 2025 bond raises did not have a specific designated use, and the equity placements were also not assigned a formal earmark. So it would be wrong to write that the company has already funded the merger through those actions. But a narrower inference is fair: the timing shows that the company entered the merger window after a sequence of equity and debt taps, and yet the cash leg of the deal is still much larger than any single disclosed financing action.

That is why the January 2026 Harel placement matters without resolving the whole issue. It adds roughly NIS 180 million of equity after the balance-sheet date, so it clearly improves the capital cushion. But it is not a full funding bridge. As long as there is no explicit disclosed financing path for the NIS 1.24 billion cash leg, the reasonable reading is that the deal depends not only on market access, but also on the willingness of existing and new financiers to complete the gap without materially changing the funding terms.

What Will Decide Whether This Is a Growth Deal or a Lender Test

Three things will determine the right market read in the coming months.

• Lender approvals. This is the first gate. If the consents arrive, the friction will look real but manageable. If they are delayed or force a reopening of terms, that will be evidence that the merger is pressing harder on the financing layer than the initial headline implied.
• Calm on the creditor side. The trustee notice opened an objection window, and the merger agreement itself requires a clean path with creditors and secured creditors. A large deal can survive strategic debate. It becomes much more fragile when creditor uncertainty enters the process.
• Proof of interim-period flexibility. As long as closing is not immediate, and the company is restricted to ordinary-course conduct and distributions of no more than NIS 25 million, investors should ask whether there is enough flexibility to carry both the waiting period and the transaction itself.

The bottom line is focused. The Acro merger may well become a growth engine, but as of the report date it is first and foremost a lender-consent test. The reported covenant ratios do not yet tell a story of an immediate wall. What they do tell is that if a wall appears, it is more likely to come through a missing consent than through a ratio table that has already broken.